azoles
Mechanisms of ResistanceA Systematic Screen Reveals a Diverse Collection of Medications That Induce Antifungal Resistance in Candida SpeciesThe increasing incidence of and high mortality rates associated with invasive fungal infections (IFIs) impose an enormous clinical, social, and economic burden on humankind. In addition to microbiological resistance to existing antifungal drugs, the large number of unexplained treatment failures is a serious concern.
SusceptibilityLoss of C-5 Sterol Desaturase Activity in Candida albicans: Azole Resistance or Merely Trailing Growth?Increased expression of drug efflux pumps and changes in the target enzyme Erg11p are known to contribute to azole resistance in Candida albicans, one of the most prevalent fungal pathogens. Mutations that inactivate ERG3, which encodes sterol Δ5,6-desaturase, also confer in vitro azole resistance.
SusceptibilityImplications of the EUCAST Trailing Phenomenon in Candida tropicalis for the In Vivo Susceptibility in Invertebrate and Murine Models...Candida tropicalis isolates often display reduced but persistent growth (trailing) over a broad fluconazole concentration range during EUCAST susceptibility testing. Whereas weak trailing (<25% of the positive growth control) is common and found not to impair fluconazole efficacy, we investigated if more pronounced trailing impacted treatment efficacy.
Mechanisms of ResistanceLimited ERG11 Mutations Identified in Isolates of Candida auris Directly Contribute to Reduced Azole SusceptibilityMultiple Erg11 amino acid substitutions were identified in clinical isolates of Candida auris originating from India and Colombia. Elevated azole MICs were detected in Saccharomyces cerevisiae upon heterologous expression of C. auris...
SusceptibilityAPX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference MethodAPX001A is the active moiety of the first-in-class drug candidate APX001. So far, most susceptibility testing studies have examined ≤30 isolates/species, and only one used the EUCAST method.
Epidemiology and SurveillanceIn Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference LaboratoriesMonitoring antifungal susceptibility patterns for new and established antifungal agents seems prudent given the increasing prevalence of uncommon species associated with higher antifungal resistance. We evaluated the activity of isavuconazole against 4,856 invasive yeasts and molds collected worldwide.
- Biologic Response ModifiersCommonly Used Oncology Drugs Decrease Antifungal Effectiveness against Candida and Aspergillus Species